MARKET

IMRNW

Immuron Ltd
IMRNW
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-34.2332
146.40
0.9494
-
BRIEF-Immuron US DoD Naval Medical Research Center Receives Feedback On on IND Application For New Campylobacter ETEC Therapeutic
BRIEF-Immuron US DoD Naval Medical Research Center Receives Feedback On on IND Application For New Campylobacter ETEC Therapeutic
Reuters · 07/26 10:07
Immuron North American Travelan® Sales up 494% and Global sales up 431%
Highlights: North American FY22 Travelan® sales increased by +494% to $0.6MGlobal sales increased by 431% to $0.9MAustralian FY22 sales increased by 318% to $0.3M MELBOURNE, Australia, July 11, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IM...
GlobeNewswire · 07/11 10:00
Immuron Receives European Patent Notification on Drug Composition to Treat Clostridioides difficile Associated Disease
MELBOURNE, Australia, July 07, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated pat...
GlobeNewswire · 07/07 10:00
US Department of Defense Uniformed Services University Clinical Evaluation of Travelan™
UPDATE Key Points Manufacture Completed of investigational medical products to be clinically evaluated by the Uniformed Services University (USU). The clinical program aims to determine the comparative efficacy of Travelan® with two third party non-antibio...
GlobeNewswire · 05/09 10:00
Immuron appoints Mr. Steven Lydeamore as Chief Executive Officer
MELBOURNE, Australia, May 05, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian biopharmaceutical company focused on developing and commercializing oral immunotherapeutics for the prevention and treatment of gut mediated path...
GlobeNewswire · 05/06 00:22
Immuron Travelan® Global sales up 216%
Key Highlights: North American Travelan® sales up by 185% YoY in Q3 FY22Global sales up 216% YoY in Q3 FY22.YTD March 31, FY22 worldwide Travelan® sales reached AU $392K, increasing 340% YoY. MELBOURNE, Australia, April 27, 2022 (GLOBE NEWSWIRE) -- Immuron...
GlobeNewswire · 04/27 10:00
Immuron new MTEC project proposal “Development of Oral Immunotherapy for the Prevention of Bacterial Diarrheal Disease”
Key Highlights: Immuron’s request for AU$5.4M (US$4M) additional funding from the U.S. Department of Defense for Travelan considered to be ‘eligible for award’Travelan Investigational New Drug (IND) application advancesClinical trial Synopsis complete and ...
GlobeNewswire · 04/19 11:33
We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Simply Wall St. · 03/25 09:21
More
No Data
Learn about the latest financial forecast of IMRNW. Analyze the recent business situations of Immuron Ltd through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
No Data
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Pharmaceuticals
-1.17%
Pharmaceuticals & Medical Research
-1.16%
Key Executives
Non-Executive Chairman/Independent Director
Roger Aston
Chief Operating Officer
Jerry Kanellos
Other
Dan Peres
Secretary
Phillip Hains
Director
Ravi Savarirayan
Non-Executive Director
Stephen Anastasiou
Non-Executive Director
Daniel Pollock
Non-Executive Independent Director
Paul Brennan
No Data
No Data

Webull offers kinds of Immuron Ltd stock information, including NASDAQ:IMRNW real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMRNW stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMRNW stock methods without spending real money on the virtual paper trading platform.